Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Jackson Creek Investment Advisors LLC

Jackson Creek Investment Advisors LLC reduced its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 30.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 21,591 shares of the biotechnology company's stock after selling 9,369 shares during the period. Corcept Therapeutics comprises 0.8% of Jackson Creek Investment Advisors LLC's holdings, making the stock its 5th largest position. Jackson Creek Investment Advisors LLC's holdings in Corcept Therapeutics were worth $2,466,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of CORT. Proficio Capital Partners LLC purchased a new position in shares of Corcept Therapeutics in the fourth quarter valued at approximately $1,597,000. Raymond James Financial Inc. purchased a new position in shares of Corcept Therapeutics in the fourth quarter valued at approximately $12,084,000. HighTower Advisors LLC lifted its position in Corcept Therapeutics by 30.7% during the fourth quarter. HighTower Advisors LLC now owns 93,677 shares of the biotechnology company's stock worth $4,720,000 after buying an additional 22,011 shares in the last quarter. Avantax Advisory Services Inc. purchased a new position in Corcept Therapeutics during the fourth quarter worth approximately $293,000. Finally, Swiss National Bank increased its stake in Corcept Therapeutics by 0.9% during the fourth quarter. Swiss National Bank now owns 184,965 shares of the biotechnology company's stock worth $9,320,000 after acquiring an additional 1,700 shares during the last quarter. 93.61% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Wall Street Zen cut Corcept Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, May 14th. Truist Financial set a $135.00 price objective on Corcept Therapeutics in a research note on Tuesday, May 6th. HC Wainwright dropped their price objective on Corcept Therapeutics from $150.00 to $145.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. Piper Sandler lifted their price objective on Corcept Therapeutics from $128.00 to $131.00 and gave the company an "overweight" rating in a research note on Thursday, April 3rd. Finally, Canaccord Genuity Group lifted their price objective on Corcept Therapeutics from $130.00 to $142.00 and gave the company a "buy" rating in a research note on Tuesday, April 1st. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $138.25.

Corcept Therapeutics Trading Down 3.1%

CORT traded down $2.24 on Friday, hitting $70.86. 563,090 shares of the company were exchanged, compared to its average volume of 1,186,997. Corcept Therapeutics Incorporated has a twelve month low of $32.33 and a twelve month high of $117.33. The company has a market cap of $7.51 billion, a price-to-earnings ratio of 61.09 and a beta of 0.15. The firm has a 50-day moving average price of $72.75 and a two-hundred day moving average price of $67.23.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.17. The company had revenue of $157.21 million during the quarter, compared to the consensus estimate of $177.93 million. Corcept Therapeutics had a return on equity of 20.40% and a net margin of 19.33%. Corcept Therapeutics's revenue for the quarter was up 7.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.25 EPS. Equities analysts expect that Corcept Therapeutics Incorporated will post 1.36 EPS for the current year.

Insider Activity at Corcept Therapeutics

In other Corcept Therapeutics news, insider William Guyer sold 20,000 shares of Corcept Therapeutics stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $72.42, for a total transaction of $1,448,400.00. Following the completion of the sale, the insider directly owned 5,487 shares of the company's stock, valued at $397,368.54. The trade was a 78.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Sean Maduck sold 20,000 shares of Corcept Therapeutics stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $79.08, for a total value of $1,581,600.00. Following the sale, the insider directly owned 17,705 shares of the company's stock, valued at $1,400,111.40. This trade represents a 53.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 225,233 shares of company stock worth $17,016,443 over the last three months. Company insiders own 20.80% of the company's stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.